Tirelizumab
Showing 1 - 25 of 38
Nasopharyngeal Carcinoma Trial in Zhongshan (Anrotinib plus Tirelizumab)
Recruiting
- Nasopharyngeal Carcinoma
- Anrotinib plus Tirelizumab
-
Zhongshan, Guangdong, ChinaZhongshan City People's Hospital
Jul 31, 2023
PFS Trial (Decitabine Injection, tirelizumab)
Not yet recruiting
- PFS
- Decitabine Injection
- tirelizumab
- (no location specified)
Nov 24, 2022
TNBC - Triple-Negative Breast Cancer Trial in Wuhan (Utidelone, Tirelizumab, Bevacizumab)
Recruiting
- TNBC - Triple-Negative Breast Cancer
- Utidelone
- +2 more
-
Wuhan, Hubei, ChinaTongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 5, 2023
Gastric Cancer Trial in Yixing (tirelizumab, chemo with oxaliplatin + heroda)
Recruiting
- Gastric Cancer
- tirelizumab
- chemotherapy with oxaliplatin + heroda
-
Yixing, Jiangsu, ChinaYixing People's Hospital
May 3, 2023
Head and Neck Squamous Cell Carcinoma, Oral Cancer Trial in Guangzhou (Tirelizumab ,+Carboplatin+albumin-bound paclitaxel)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- Oral Cancer
- Tirelizumab ,+Carboplatin+albumin-bound paclitaxel
-
Guangzhou, Guangdong, ChinaSun yat-sun memorial hospital
Jul 10, 2023
NSCLC Trial (Tirelizumab;Chemotherapy monotherapy)
Not yet recruiting
- Non-small Cell Lung Cancer
- Tirelizumab；Chemotherapy monotherapy
- (no location specified)
Jul 27, 2023
Metastatic Breast Cancer in the Liver Trial in Shanghai (Cryoablation Combined with Tirelizumab and Bevacizumab)
Recruiting
- Metastatic Breast Cancer in the Liver
- Cryoablation Combined with Tirelizumab and Bevacizumab
-
Shanghai, Shanghai, China
- +1 more
Jun 6, 2022
Carcinoma, Non-Small Cell Lung Trial (sequential DEB-BACE and Arotinib and Tirelizumab, DEB-BACE alone)
Not yet recruiting
- Carcinoma, Non-Small Cell Lung
- sequential DEB-BACE and Arotinib and Tirelizumab
- DEB-BACE alone
- (no location specified)
May 14, 2022
Breast Cancer, Neoadjuvant Therapy Trial in Wuhan (Disitamab Vedotin combined with Tislelizumab)
Recruiting
- Breast Cancer
- Neoadjuvant Therapy
- Disitamab Vedotin combined with Tislelizumab
-
Wuhan, Hubei, ChinaWuhanHU
May 16, 2023
Nasopharyngeal Carcinoma Trial (Tirelizumab, salvage surgery)
Not yet recruiting
- Nasopharyngeal Carcinoma
- Tirelizumab
- salvage surgery
- (no location specified)
Oct 22, 2021
Advanced Gastroesophageal Adenocarcinoma, First-line Therapy, PDL1 CPS < 5 Trial (CAPOX combined with bevacizumab and
Not yet recruiting
- Advanced Gastroesophageal Adenocarcinoma
- +2 more
- CAPOX combined with bevacizumab and Tislelizumab
- (no location specified)
Mar 17, 2022
Advanced Melanoma Trial in Zhengzhou (Tislelizumab Injection)
Not yet recruiting
- Advanced Melanoma
- Tislelizumab Injection
-
Zhengzhou, Henan, ChinaDepartment of Bone and Soft Tissue ,Henan Cancer Hospital
Aug 4, 2022
Stomach Cancer Trial (Tirelizumab, Trastuzumab, Docetaxel)
Not yet recruiting
- Stomach Cancer
- Tirelizumab
- +4 more
- (no location specified)
Aug 19, 2021
Esophageal Squamous Cell Carcinoma Trial in Shanghai (Tirelizumab, Nab paclitaxel, Carboplatin)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Tirelizumab
- +3 more
-
Shanghai, Shanghai, ChinaRuijin hospital, Shanghai jiaotong university school of medicine
Nov 6, 2023
HER2-positive Gastric Cancer Trial in Jinan, Qingdao, Yantai (Disitamab vedotin, Tislelizumab, S1)
Not yet recruiting
- HER2-positive Gastric Cancer
- Disitamab vedotin
- +2 more
-
Jinan, Shandong, China
- +6 more
Oct 16, 2022
Esophageal Squamous Cell Carcinoma Trial in Chengdu (Tirelizumab, Paclitaxel, Carboplatin)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Tirelizumab
- +3 more
-
Chengdu, Sichuan, ChinaSichuan Cancer Hospital and Research Institute
Feb 8, 2022
Non Small Cell Lung Cancer, Endostatin Trial in Guangzhou (Endostatin)
Not yet recruiting
- Non Small Cell Lung Cancer
- Endostatin
-
Guangzhou, Guangdong, ChinaAffiliated Cancer Hospital and Institute of Guangzhou Medical Un
Jul 4, 2022
Immunotherapy, Adjuvant Therapy, Colon Cancer Trial in Tianjin (Tirelizumab)
Recruiting
- Immunotherapy
- +3 more
- Tirelizumab
-
Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Jul 11, 2021
Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma Trial in Shanghai (Vitamin E, Fruquintinib, Tislelizumab)
Not yet recruiting
- Colorectal Cancer
- Microsatellite Stable Colorectal Carcinoma
- Vitamin E
- +2 more
-
Shanghai, Shanghai, China270 Dongan Road, Fudan University Shanghai Cancer Center
Mar 5, 2023
Locally Advanced Gastric Adenocarcinoma Trial in Xi'an (Tislelizumab combined with Oxaliplatin and Capecitabine)
Active, not recruiting
- Locally Advanced Gastric Adenocarcinoma
- Tislelizumab combined with Oxaliplatin and Capecitabine
-
Xi'an, Shaanxi, ChinaXijing Hospital of Digestive Diseases
Aug 17, 2022
Untreated Advanced NSCLC Trial in Fuzhou (Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and
Recruiting
- Untreated Advanced Non-small Cell Lung Cancer
- Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy
-
Fuzhou, Fujian, ChinaFujian Cancer Hospital
Nov 13, 2023
NSCLC Trial in Chongqing (procedure, drug, radiation)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- bronchial artery interventional therapy
- +3 more
-
Chongqing, Chongqing, ChinaDaping Hospital, Third Military Medical University
May 27, 2023
Rectal Cancer Trial in Chongqing (CIETAI-R)
Recruiting
- Rectal Cancer
- CIETAI-R
-
Chongqing, Chongqing, ChinaDaping Hospital, Third Military Medical University
Jul 21, 2023
Lung Cancer, Immune Checkpoint Inhibitor, Radiotherapy Trial in Chongqing (Super-hyperfractionation Pulse Radiotherapy)
Recruiting
- Lung Cancer
- +2 more
- Super-hyperfractionation Pulse Radiotherapy
-
Chongqing, Chongqing, China
- +1 more
Feb 22, 2023
Tislelizumab, Lenvatinib, TACE Trial in Nanning (Tislelizumab and Lenvatinib)
Active, not recruiting
- Tislelizumab
- +3 more
- Tislelizumab and Lenvatinib
-
Nanning, Guangxi, ChinaThe Affiliated Cancer Hospital of Guangxi Medical University
Jan 25, 2023